Home » Stocks » EDSA

Edesa Biotech, Inc. (EDSA)

Stock Price: $5.34 USD -0.45 (-7.77%)
Updated Jan 25, 2021 2:32 PM EST - Market open
Market Cap 60.93M
Revenue (ttm) 328,801
Net Income (ttm) -6.36M
Shares Out 8.61M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $5.34
Previous Close $5.79
Change ($) -0.45
Change (%) -7.77%
Day's Open 5.90
Day's Range 5.20 - 5.90
Day's Volume 191,619
52-Week Range 1.64 - 9.45


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 2 weeks ago

TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colom...

Accesswire - 3 weeks ago

TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, ...

24/7 Wall Street - 5 months ago

Edesa Biotech Inc. (NASDAQ: EDSA) joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study.

Benzinga - 7 months ago

Canadian biopharma Edesa Biotech Inc (NASDAQ: EDSA) is seeing its shares surge higher Monday after it announced regulatory approval to begin a late-stage study of its investigational asset for...

Seeking Alpha - 1 year ago

Edesa Biotech received go ahead from FDA to initiate its phase 2b study using EB01 to treat patients with chronic contact dermatitis.

InvestorPlace - 1 year ago

Edesa Biotech (EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).

Benzinga - 1 year ago

Edesa Biotech Inc., shares were trading higher Thursday after the company received Food and Drug Administration approval to proceed with its U.S.

About EDSA

Edesa Biotech, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. ... [Read more...]

Dr. Pardeep Nijhawan FRCPC, M.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Edesa Biotech stock is "Strong Buy" and the 12-month stock price forecast is 15.50.

Price Target
Analyst Consensus: Strong Buy